About Phosphoserine aminotransferase
Phosphoserine aminotransferase (PSAT1) is a protein
from Homo sapiens identified by UniProt accession
Q9Y617, 370 residues long.
MolForge cross-references it against 0 known binders and
190 disease associations.
Target properties
| Protein name | Phosphoserine aminotransferase |
| UniProt accession | Q9Y617 |
| Gene | PSAT1 |
| Organism | Homo sapiens |
| Length | 370 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (190)
Diseases linked to this target (Open Targets).
- Neu-Laxova syndrome 2 · score 0.78
- Phosphoserine aminotransferase deficiency · score 0.69
- PSAT deficiency · score 0.65
- Neu-Laxova syndrome · score 0.46
- neurometabolic disorder due to serine deficiency · score 0.37
- mean corpuscular volume · score 0.31
- adolescent idiopathic scoliosis · score 0.30
- venous thromboembolism · score 0.29
- body mass index · score 0.22
- type 2 diabetes mellitus · score 0.20
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9Y617-F1 | alphafold | PREDICTED | 97.07 | — |
Amino-acid sequence (370 residues)
MDAPRQVVNF GPGPAKLPHS VLLEIQKELL DYKGVGISVL EMSHRSSDFA KIINNTENLV RELLAVPDNY KVIFLQGGGC GQFSAVPLNL IGLKAGRCAD YVVTGAWSAK AAEEAKKFGT INIVHPKLGS YTKIPDPSTW NLNPDASYVY YCANETVHGV EFDFIPDVKG AVLVCDMSSN FLSKPVDVSK FGVIFAGAQK NVGSAGVTVV IVRDDLLGFA LRECPSVLEY KVQAGNSSLY NTPPCFSIYV MGLVLEWIKN NGGAAAMEKL SSIKSQTIYE IIDNSQGFYV CPVEPQNRSK MNIPFRIGNA KGDDALEKRF LDKALELNML SLKGHRSVGG IRASLYNAVT IEDVQKLAAF MKKFLEMHQL
Explore Phosphoserine aminotransferase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets